» Articles » PMID: 34055608

Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 May 31
PMID 34055608
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate isocitrate dehydrogenase (IDH) status in clinically diagnosed grade II~IV glioma patients using the 2016 World Health Organization (WHO) classification based on MRI parameters.

Materials And Methods: One hundred and seventy-six patients with confirmed WHO grade II~IV glioma were retrospectively investigated as the study set, including lower-grade glioma (WHO grade II, n = 64; WHO grade III, n = 38) and glioblastoma (WHO grade IV, n = 74). The minimum apparent diffusion coefficient (ADCmin) in the tumor and the contralateral normal-appearing white matter (ADCn) and the rADC (ADCmin to ADCn ratio) were defined and calculated. Intraclass correlation coefficient (ICC) analysis was carried out to evaluate interobserver and intraobserver agreement for the ADC measurements. Interobserver agreement for the morphologic categories was evaluated by Cohen's kappa analysis. The nonparametric Kruskal-Wallis test was used to determine whether the ADC measurements and glioma subtypes were related. By univariable analysis, if the differences in a variable were significant (P<0.05) or an image feature had high consistency (ICC >0.8; κ >0.6), then it was chosen as a predictor variable. The performance of the area under the receiver operating characteristic curve (AUC) was evaluated using several machine learning models, including logistic regression, support vector machine, Naive Bayes and Ensemble. Five evaluation indicators were adopted to compare the models. The optimal model was developed as the final model to predict IDH status in 40 patients with glioma as the subsequent test set. DeLong analysis was used to compare significant differences in the AUCs.

Results: In the study set, six measured variables (rADC, age, enhancement, calcification, hemorrhage, and cystic change) were selected for the machine learning model. Logistic regression had better performance than other models. Two predictive models, model 1 (including all predictor variables) and model 2 (excluding calcification), correctly classified IDH status with an AUC of 0.897 and 0.890, respectively. The test set performed equally well in prediction, indicating the effectiveness of the trained classifier. The subgroup analysis revealed that the model predicted IDH status of LGG and GBM with accuracy of 84.3% (AUC = 0.873) and 85.1% (AUC = 0.862) in the study set, and with the accuracy of 70.0% (AUC = 0.762) and 70.0% (AUC = 0.833) in the test set, respectively.

Conclusion: Through the use of machine-learning algorithms, the accurate prediction of IDH-mutant versus IDH-wildtype was achieved for adult diffuse gliomas noninvasive MR imaging characteristics, including ADC values and tumor morphologic features, which are considered widely available in most clinical workstations.

Citing Articles

Multimodal MRI and H-MRS for Preoperative Stratification of High-Risk Molecular Subtype in Adult-Type Diffuse Gliomas.

Han X, Xiao K, Bai J, Li F, Cui B, Cheng Y Diagnostics (Basel). 2024; 14(22).

PMID: 39594235 PMC: 11592885. DOI: 10.3390/diagnostics14222569.


Ultra-high b-value DWI accurately identifies isocitrate dehydrogenase genotypes and tumor subtypes of adult-type diffuse gliomas.

Wang X, Shu X, He P, Cai Y, Geng Y, Hu X Eur Radiol. 2024; 34(10):6751-6762.

PMID: 38528135 DOI: 10.1007/s00330-024-10708-5.


The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.

Yu M, Ge Y, Wang Z, Zhang Y, Hou X, Chen H J Neurooncol. 2024; 167(2):305-313.

PMID: 38424338 DOI: 10.1007/s11060-024-04609-2.


Evaluations of the diagnostic performance of ZOOMit diffusion-weighted imaging and conventional diffusion-weighted imaging for breast lesions.

Weng C, Yang Y, Yang L, Hu C, Ma X, Li G Quant Imaging Med Surg. 2023; 13(12):8478-8488.

PMID: 38106248 PMC: 10722069. DOI: 10.21037/qims-23-415.


Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.

Yang X, Hu C, Xing Z, Lin Y, Su Y, Wang X Eur Radiol. 2023; 33(10):7003-7014.

PMID: 37133522 DOI: 10.1007/s00330-023-09695-w.


References
1.
Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D . Noninvasive Assessment of Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging. AJNR Am J Neuroradiol. 2017; 38(6):1138-1144. PMC: 7960080. DOI: 10.3174/ajnr.A5171. View

2.
Patel S, Poisson L, Brat D, Zhou Y, Cooper L, Snuderl M . T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res. 2017; 23(20):6078-6085. DOI: 10.1158/1078-0432.CCR-17-0560. View

3.
Jiang H, Zou B, Xu C, Xu J, Yan Tang Y . SVM-Boosting based on Markov resampling: Theory and algorithm. Neural Netw. 2020; 131:276-290. DOI: 10.1016/j.neunet.2020.07.036. View

4.
Wang Q, Zhang J, Xu X, Chen X, Xu B . Diagnostic performance of apparent diffusion coefficient parameters for glioma grading. J Neurooncol. 2018; 139(1):61-68. DOI: 10.1007/s11060-018-2841-5. View

5.
Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S . Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2018; 2(4):230-243. PMC: 5829945. DOI: 10.1136/svn-2017-000101. View